Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

Home
/
update
/
details

Clario and PathAI Join Forces to Streamline GI Clinical Trials with Integrated Solutions

NextEdge Admin

14 Oct 2024

2 min 10 sec

Clario has formed a strategic partnership with PathAI, an AI-powered digital pathology provider, to streamline gastrointestinal (GI) clinical trials. This collaboration aims to create a comprehensive solution that integrates anatomical pathology services with advanced video endoscopy assessments, offering a single-vendor experience for contract research organizations (CROs) and sponsors.

The initiative will encompass a full end-to-end process, including training, logistics, tissue processing, slide digitization, image analysis, and data transfer, all managed under expert medical and scientific oversight. This partnership is set to simplify workflows at clinical trial sites, enhancing training, reporting, and document management.

Marcela Vieira, Clario's gastroenterology medical director, expressed excitement about the collaboration, highlighting that it combines their expertise in GI trials—backed by over 130 studies using advanced imaging technologies—with PathAI’s innovative capabilities in patient care and research. The integration of endoscopy and histopathology is expected to open new avenues for clinical research.

PathAI will contribute its network of expert GI pathologists and focus on improving the handling of specimens and histological assessments. Their AI-driven solutions are designed to enhance evaluations for ulcerative colitis (UC), minimize variability in histological scoring, and expedite biomarker discovery.

Matt Grow, chief business officer of PathAI Biopharma, noted that this partnership will provide a state-of-the-art approach to assessing therapeutic efficacy in inflammatory bowel disease (IBD) clinical trials, ultimately accelerating therapy development.